| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fb8172f437610bb6fcea6b77aea9ae8a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5abe4fd46dc00753c26fb294d252206a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d13f7b60be54e9c5705f69abc7157092
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9bd2886de91c1a6d471cc7578391b820
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_942517ed4063a7d37bc616afc23c498d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a16702197fffa60e954fb1e14e8d083 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-04 |
| filingDate |
2006-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3757c765331558efb1043128900523dc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f4325072e552497866d7b307895ab5c2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4a2786ec3344a5f21ce580ee491764c5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_512568fed418839c3434f9ec8f3a4532
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f240305b5c678d047fb51529b02e24b4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df9c98421aee46983ca0ee4072a15be2 |
| publicationDate |
2009-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2009214673-A1 |
| titleOfInvention |
Use of Hydrogen sulfide in the treatment of eye diseases |
| abstract |
Topical administration of a generator of H 2 S in biological tissues for the treatment of eye disorders, such as glaucoma. NaHS caused a time-dependent decrease in intrancular pressure in nomotensive, conscious albino rabbits indicating a similar role for H 2 S in the regulation of aqueous humor dynamics in animals and humans. H 2 S donors, NaHS and Na2S, inhibited field-stimulated [3H]NE release from porcine isolated iris-ciliary bodies and produced relaxation of pre-contracted iris muscle strips indicating a pharmacological role for H 2 S in the anterior uvea. The observation that donors of H 2 S can alter sympathetic neurotransmission and induce an inhibitory action on iris smooth muscle suggests that this gas has the potential to influence several physiological/pathological processes in the eye. The ability of NaHS or Na2S to inhibit [3H]NE release mimics the well-established action some antiglaucoma drugs (e.g. α2-adrenoceptor agonists, prostaglandins) on sympathetic neurotransmission in the anterior uvea and can be used to reduce IOP in animals and humans. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10688096-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8865684-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2013131028-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2017327196-A1 |
| priorityDate |
2005-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |